Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Prostatic Neoplasms 21Glioblastoma 19Lung Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 12Glioma 12Neoplasms 11Oropharyngeal Neoplasms 10Head and Neck Neoplasms 10Esophageal Neoplasms 8Astrocytoma 8Sarcoma 7Neoplasm Metastasis 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Colorectal Neoplasms 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Lymphoma, Follicular 5Hodgkin Disease 5Gliosarcoma 5Carcinoma, Hepatocellular 5Carcinoma 5Burkitt Lymphoma 5

Interventions

Magnetic Resonance Spectroscopy 2sapanisertib 1pertuzumab 1patritumab deruxtecan 1gadopiclenol 1gadobutrol 1fludarabine phosphate 1fludarabine 1aldesleukin 1Trastuzumab 1Spinal Puncture 1Specimen Handling 1Radiotherapy 1Nivolumab 1Methotrexate 1Mesna 1Interleukin-2 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Neoplasms × Radiotherapy × 90 days × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡